Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
10 drugs in development
By Therapeutic Area
top 1
R&D Momentum
83/100
Pipeline Velocity
62/100
Trial Completion Rate
83/100
Pipeline Concentration
50/100
Pipeline Freshness
66/100
Activity
Last 14 days
Addiction Potential of Very Low Nicotine Filtered Little Cigars
Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma
Implementation of a Navigation Program for Breast Cancer Survivors
Video Intervention to Address Pre-Test Patient Education for Tumor Genomic Testing
Effect of Early Integrated Neuropsychological Care in Patients With Brain Metastases - A Phase 2 Randomized Controlled Trial
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)